We previously reported that although EGFR mutations are not a feature of pure squamous
cell carcinomas (SCC) of the lung, these mutations do occur in adenosquamous carcinomas …

Whether EGFR mutation occurs in lung squamous cell carcinoma (SCC) remains a
controversial issue. Although numerous trials have shown positive response to tyrosine …

Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …

Hellmann et al. Journal of Thoracic Oncology®• Volume 9, Number 10, October 2014
location of S768 is outside the erlotinib binding pocket, which would assert no immediate …

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung …

8038 Background: EGFR-mutant “oncogene-addicted” cancers are a distinct form of NSCLC
that can be targeted with erlotinib (Paz-Ares et al. ASCO 2006). Methods: From April 2005 to …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Background: Lung cancer is the leading cause of cancer mortality. Non–small-cell lung
cancer (NSCLC) comprises up to 90% of all lung cancers. Conventional treatment for …

Background Non-small cell lung cancer (NSCLC) has a 5-year survival of 5–16%. Epidermal
growth factor receptor (EGFR) mutations, in most cases, confer sensitivity to EGFR tyrosine …

We report on a patient with metastatic lung adenocarcinoma who underwent testing for
EGFR mutations in a pleural effusion that failed to show any alterations and received …